羰基铁与右旋糖酐铁对幼年慢性肾脏病小鼠及患儿骨健康的不良影响
该研究在腺嘌呤诱导和5/6肾切除两种幼年CKD小鼠模型中评估口服与胃肠外铁剂对骨转录组、组织学及形态计量学的影响,并在CKD患儿队列中分析铁治疗与骨转换标志物的关系。结果显示两种铁剂均改善贫血并降低骨Fgf23表达,但抑制骨形成相关基因、导致皮质骨和松质骨丢失;铁治疗患儿骨形成标志物及骨祖细胞水平更低。
要点
- 铁剂治疗改善幼年CKD小鼠贫血并降低骨Fgf23表达,但抑制骨形成基因并导致皮质骨与松质骨丢失。
- 未治疗CKD小鼠骨吸收已激活,铁剂治疗对骨吸收无额外影响。
- 铁治疗CKD患儿骨形成标志物(BALP、PINP)及循环骨祖细胞水平低于未治疗患儿,且独立于年龄、性别和GFR。
核心结论
- 铁剂治疗对幼年CKD小鼠骨健康产生不良影响,并与CKD患儿骨形成标志物水平降低相关。
研究设计与样本
- 研究在腺嘌呤诱导和5/6肾切除两种幼年CKD小鼠模型中评估口服与胃肠外铁剂对骨转录组、骨组织学及形态计量学的影响。
- 同时在一组CKD患儿队列中评估骨转换生物标志物与铁状态的关系。
主要发现
- 两种铁剂治疗均有效改善CKD小鼠贫血,并降低骨Fgf23表达。
- 铁剂治疗抑制骨形成相关基因,导致CKD小鼠皮质骨和松质骨丢失。
- 未治疗CKD小鼠骨吸收激活,铁剂治疗对骨吸收无额外影响。
- 铁治疗CKD患儿循环骨形成标志物(骨特异性碱性磷酸酶和1型前胶原氨基端前肽)水平及循环骨祖细胞数量低于未治疗患儿。
- 上述差异独立于年龄、性别和肾小球滤过率。
临床怎么用
- 对幼年CKD患者使用铁剂治疗贫血时,需关注其对骨形成和骨量的潜在不良影响。
- 监测骨形成标志物(如骨特异性碱性磷酸酶、1型前胶原氨基端前肽)可能有助于评估铁治疗对骨健康的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is a frequent complication of chronic kidney disease (CKD), related in part to the disruption of iron metabolism. Iron therapy is very common in children with CKD and excess iron has been shown to induce bone loss in non-CKD settings, but the impact of iron on bone health in CKD remains poorly understood. Here, we evaluated the effect of oral and parenteral iron therapy on bone transcriptome, bone histology and morphometry in two mouse models of juvenile CKD (adenine-induced and 5/6-nephrectomy). Both modalities of iron therapy effectively improved anemia in the mice with CKD, and lowered bone Fgf23 expression. At the same time, iron therapy suppressed genes implicated in bone formation and resulted in the loss of cortical and trabecular bone in the mice with CKD. Bone resorption was activated in untreated CKD, but iron therapy had no additional effect on this. Furthermore, we assessed the relationship between biomarkers of bone turnover and iron status in a cohort of children with CKD. Children treated with iron had lower levels of circulating biomarkers of bone formation (bone-specific alkaline phosphatase and the amino-terminal propeptide of type 1 procollagen), as well as fewer circulating osteoblast precursors, compared to children not treated with iron. These differences were independent of age, sex, and glomerular filtration rate. Thus, iron therapy adversely affected bone health in juvenile mice with CKD and was associated with low levels of bone formation biomarkers in children with CKD.
引用
- Patino E, Doty SB, Bhatia D, et al. Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease. Kidney Int. 2020. PMID: 32574618. doi:10.1016/j.kint.2020.05.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。